Protagonist Therapeutics
PTGX
PTGX
85 hedge funds and large institutions have $605M invested in Protagonist Therapeutics in 2020 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 42 increasing their positions, 14 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
85
Holders Change
+8
Holders Change %
+10.39%
% of All Funds
1.75%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
25
Increased
42
Reduced
14
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$38.9M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$29.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.9M |
| 4 |
DM
Deerfield Management
New York
|
+$17.9M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$17.7M |
Top Sellers
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.71M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$3.31M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$1.61M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.12M |
| 5 |
VA
VR Adviser
New York
|
-$799K |
